Back to search

South Dakota State University

Development of a Novel Nanotechnology-Based Vaccine Adjuvant and Delivery System for Systemic and Mucosal Immunity

Abstract

dc:description.abstract

Many serious infections for which there are no existing vaccines, enter by a mucosal route such as HIV, influenza, and tuberculosis, etc. Therefore, designing safe and effective mucosal vaccines that elicit robust immune response at mucosal sites is still a major challenge without a safe mucosal adjuvant. Previously, our laboratory had discovered inulin acetate as a novel toll-like-receptor-4 agonist (adjuvant). The study in this dissertation explored the application of nanoparticles prepared with inulin acetate (InAc-NPs) as a vaccine adjuvant and delivery system for enhancing mucosal immunity. The rationale behind selecting InAc-NPs is their proven ability to activate strong systemic immunity along with an extensive understanding of their mechanisms of activation. In chapter-II, we have clearly established, through intranasal vaccinations in mice, that InAc-NPs could generate strong systemic and mucosal antibodies (IgG1, IgG2a, sIgA) and cytokine response that represents both humoral and cellular immunity. InAc-NPs efficiently delivered the antigen into macrophages as well as activated them to release inflammatory cytokines such as TNF-α, which have been attributed for robust immune response in mice. In chapter-III, the efficacy of InAc-NPs as a vaccine adjuvant in swine model was established for the first time along with the safety profile in mice. InAc-NPs are proficient in stimulation of swine PBMCs to secrete cytokines such as IL-6, IL12, and IFN-. Importantly, InAc-NPs carrying the influenza peptide (M2e) produced higher mucosal and systemic antibodies compared to unadjuvanted antigen in pigs. The study, for the first time, showed InAc as a vaccine adjuvant in pigs that will have significant implications in swine industry and human health. In chapter-IV, InAc-NPs were explored as a delivery system to carry TLR7 agonist C-563 to its target site in the phagosomes/endosomes of antigen presenting cells. InAc-NPs loaded with C563 provided a unique dual adjuvant and/or a delivery system for vaccines that require robust immune response such as cancer or influenza vaccines. In conclusion, we have demonstrated the ability of InAc-NPs as a robust vaccine adjuvant and a delivery platform that provides strong systemic and mucosal immunity, which will have significant implications in fighting challenging diseases such as HIV, influenza, cancer, and tuberculosis.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation - Open Access
Discipline thesis:degree_discipline
Pharmaceutical Sciences

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bakkari, Mohammed Ali
Contributors dc:contributor
  • Hemachand Tummala

Subjects

dc:subject × 1

Rights

dc:rights

Identifiers

dc:identifier.*
Repository record dc:identifier
https://openprairie.sdstate.edu/etd/3143

Chain of custody

source
Harvested from
South Dakota State University
Base URL
openprairie.sdstate.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Bakkari, Mohammed Ali. Development of a Novel Nanotechnology-Based Vaccine Adjuvant and Delivery System for Systemic and Mucosal Immunity. Dissertation - Open Access thesis, https://openprairie.sdstate.edu/etd/3143